1Hirsch FR;Langer CJ.The role of HER2/neu expression and trastuzumab in non-small cell lung cancer[J],2004(01).
2Clamon G;Herndon J;Kern J.Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2:39810:a phase Ⅱ trial of Cancer and Leukemia Group B[J],2005(08).
5Zhang YA;Nemunaitis J;Scanlon KJ.Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice[J],2000(23).
7Salgaller M L.Technology evaluation:bevacizumab Genentech/Roche[J],2003(05).
8Soker S;Takashima S;Miao HQ.Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor[J],1998(06).
10Koomagi R;Volm M.Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry:correlation between tissue factor and angiogenesis,1998(01).
3Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol,2002,3(11) : 672-683.
4Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol, 2001,61 ( 3 ): 253-270.
5Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003,21(12): 2237-2246.
6Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitahine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial -INTACT 1. J Clin Oncol. 2004 Mar 1;22(5): 777-784.
7Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 2. J Clin Oncol,2004,22(5):785-794.
8Falardeau P, Champagne P, Poyet P, et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase Ⅲ clinical trials. Semin Oncol,2001,28(6): 620-625.
9Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA,2003,290(16): 2149-2158.
10Hida T, Kozaki K, Ito H, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE 522, and conventional anticancer agents. Clin Cancer Res, 2002,8 (7) : 24
